Tonix Pharmaceuticals Holding Corp (TNXP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Tonix Pharmaceuticals Holding Corp stock (TNXP) is currently trading at $15.34. Tonix Pharmaceuticals Holding Corp PS ratio (Price-to-Sales) is 15.34. Analyst consensus price target for TNXP is $54.33. WallStSmart rates TNXP as Sell.
- TNXP PE ratio analysis and historical PE chart
- TNXP PS ratio (Price-to-Sales) history and trend
- TNXP intrinsic value — DCF, Graham Number, EPV models
- TNXP stock price prediction 2025 2026 2027 2028 2029 2030
- TNXP fair value vs current price
- TNXP insider transactions and insider buying
- Is TNXP undervalued or overvalued?
- Tonix Pharmaceuticals Holding Corp financial analysis — revenue, earnings, cash flow
- TNXP Piotroski F-Score and Altman Z-Score
- TNXP analyst price target and Smart Rating
Tonix Pharmaceuticals Holding Corp
📊 No data available
Try selecting a different time range
Smart Analysis
Tonix Pharmaceuticals Holding Corp (TNXP) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Tonix Pharmaceuticals Holding Corp (TNXP) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 108.80% year-over-year
Supporting Valuation Data
Tonix Pharmaceuticals Holding Corp (TNXP) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 15.3x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Tonix Pharmaceuticals Holding Corp (TNXP) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.82) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 108.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (15.34) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -64.50%, Operating Margin at -896.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -64.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 108.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TNXP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TNXP's Price-to-Sales ratio of 15.34x trades at a deep discount to its historical average of 1430.15x (51th percentile). The current valuation is 100% below its historical high of 8793.12x set in Jan 2020, and 6873% above its historical low of 0.22x in Sep 2024. Over the past 12 months, the PS ratio has compressed from ~23.5x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Tonix Pharmaceuticals Holding Corp (TNXP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Tonix Pharmaceuticals Holding Corp is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 13M with 109% growth year-over-year.
Key Findings
Revenue growing at 109% YoY, reaching 13M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of 0.00 indicates a conservative balance sheet with 190M in cash.
Free cash flow is -42M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Tonix Pharmaceuticals Holding Corp maintain 109%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 1.86, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Tonix Pharmaceuticals Holding Corp.
Bottom Line
Tonix Pharmaceuticals Holding Corp is a high-conviction growth story with revenue accelerating at 109% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Tonix Pharmaceuticals Holding Corp(TNXP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.